JW Lifescience Corporation (234080.KS)
KRW 11520.0
(-0.78%)
KRW 11520.0
(-0.78%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 46.31 Billion KRW | -31.08% |
| 2022 | 67.19 Billion KRW | 44.54% |
| 2021 | 46.48 Billion KRW | 27.23% |
| 2020 | 36.53 Billion KRW | -18.27% |
| 2019 | 44.7 Billion KRW | -18.76% |
| 2018 | 55.02 Billion KRW | -8.86% |
| 2017 | 60.37 Billion KRW | -12.16% |
| 2016 | 68.73 Billion KRW | 1.66% |
| 2015 | 67.61 Billion KRW | 9.15% |
| 2014 | 61.94 Billion KRW | -2.9% |
| 2013 | 63.79 Billion KRW | -8.55% |
| 2012 | 69.76 Billion KRW | -11.91% |
| 2011 | 79.18 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 46.35 Billion KRW | -2.68% |
| 2024 Q1 | 47.63 Billion KRW | 2.85% |
| 2023 Q4 | 46.31 Billion KRW | -13.94% |
| 2023 Q3 | 53.81 Billion KRW | 1.32% |
| 2023 Q1 | 69.59 Billion KRW | 3.57% |
| 2023 FY | 46.31 Billion KRW | -31.08% |
| 2023 Q2 | 53.11 Billion KRW | -23.68% |
| 2022 Q1 | 54.1 Billion KRW | 16.39% |
| 2022 FY | 67.19 Billion KRW | 44.54% |
| 2022 Q2 | 70.7 Billion KRW | 30.67% |
| 2022 Q3 | 73.25 Billion KRW | 3.6% |
| 2022 Q4 | 67.19 Billion KRW | -8.27% |
| 2021 FY | 46.48 Billion KRW | 27.23% |
| 2021 Q1 | 38.55 Billion KRW | 5.52% |
| 2021 Q2 | 50.14 Billion KRW | 30.06% |
| 2021 Q3 | 49.66 Billion KRW | -0.95% |
| 2021 Q4 | 46.48 Billion KRW | -6.4% |
| 2020 FY | 36.53 Billion KRW | -18.27% |
| 2020 Q1 | 38.39 Billion KRW | -14.13% |
| 2020 Q2 | 77.32 Billion KRW | 101.41% |
| 2020 Q3 | 45.86 Billion KRW | -40.68% |
| 2020 Q4 | 36.53 Billion KRW | -20.34% |
| 2019 Q3 | 46.02 Billion KRW | -6.84% |
| 2019 Q1 | 46.9 Billion KRW | -14.75% |
| 2019 FY | 44.7 Billion KRW | -18.76% |
| 2019 Q4 | 44.7 Billion KRW | -2.87% |
| 2019 Q2 | 49.4 Billion KRW | 5.32% |
| 2018 Q3 | 56.27 Billion KRW | 9.01% |
| 2018 FY | 55.02 Billion KRW | -8.86% |
| 2018 Q4 | 55.02 Billion KRW | -2.22% |
| 2018 Q2 | 51.62 Billion KRW | -5.92% |
| 2018 Q1 | 54.87 Billion KRW | -9.11% |
| 2017 Q1 | 58.73 Billion KRW | -14.55% |
| 2017 Q2 | 58.13 Billion KRW | -1.02% |
| 2017 Q3 | 64.51 Billion KRW | 10.97% |
| 2017 Q4 | 60.37 Billion KRW | -6.41% |
| 2017 FY | 60.37 Billion KRW | -12.16% |
| 2016 FY | 68.73 Billion KRW | 1.66% |
| 2016 Q4 | 68.73 Billion KRW | 11.63% |
| 2016 Q3 | 61.57 Billion KRW | -11.5% |
| 2016 Q2 | 69.57 Billion KRW | 0.0% |
| 2015 Q4 | 67.61 Billion KRW | 0.0% |
| 2015 FY | 67.61 Billion KRW | 9.15% |
| 2014 FY | 61.94 Billion KRW | -2.9% |
| 2013 FY | 63.79 Billion KRW | -8.55% |
| 2012 FY | 69.76 Billion KRW | -11.91% |
| 2011 FY | 79.18 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -17.524% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 93.306% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 87.878% |
| HANDOK Inc. | 300.01 Billion KRW | 84.563% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -51.043% |
| Yuhan Corporation | 230.07 Billion KRW | 79.87% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 88.613% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -7677.319% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 91.916% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -3488.668% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 45.617% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -7.025% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 48.816% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -74.548% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -17.524% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -19348.875% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 79.421% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 74.412% |
| JW Holdings Corporation | 554.58 Billion KRW | 91.649% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 78.74% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 78.926% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 72.802% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -0.35% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -18.13% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 73.668% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 45.492% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -17.524% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 80.346% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 90.14% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 72.802% |
| Yuhan Corporation | 230.07 Billion KRW | 79.87% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 73.234% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 30.754% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 90.101% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 72.802% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 60.963% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -14.809% |
| CKD Bio Corp. | 146.92 Billion KRW | 68.479% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 68.29% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 4.026% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -7227.683% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -0.35% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 90.105% |
| Boryung Corporation | 204.21 Billion KRW | 77.322% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 41.662% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 45.617% |